ANIMAL MODELS SHARED RESOURCE The Animal Models (AM) SR has a long and productive history providing experimental assistance to Cancer Center members. The Genetically engineered mouse models (GEMMs), Cell-line Derived Syngeneic or Xenografts (CDX) models and Patient Derived Xenografts (PDX) models are central to LCCC basic and translational research. This is an endeavor that the LCCC and UNC helped to create through the work of the late Oliver Smithies who won the Nobel Prize for his groundbreaking techniques to allow creation of gene modified mouse models. The AM SR has grown dramatically in scope and usage over the last 20 years and is now composed of services for the creation, investigation at multiple levels and imaging of animal models of cancer. These services include: innovative methods for transgenic/knockout allele production and design, generation of PDX models from primary human tumors, allele phenotyping and colony management, animal imaging and tumorigenicity studies in CDXs (both syngeneic immunocompetent and immunocompromised models), PDXs and GEMMs. The AM SR assists Cancer Center members in the planning and execution of carefully designed animal studies. The availability of this SR and its highly skilled personnel eliminates the need for Cancer Center investigators to hire similar individuals within their laboratories and ensures a high level of rigor and reproducibility for their experiments. The three arms of this SR facility; 1) GEMM production, 2) surgery on and experimental testing of syngeneic mouse, CDX and PDX mouse models, 3) translational cancer imaging, benefit from a team of three experienced Facility Directors and well-trained staff. Users of this SR benefit from significant cost reduction and decreased completion times for their studies. The AM SR requests $235,252 from the CCSG to fund this facility in fiscal year 2020; this represents approximately 6% of the total FY19 operating costs for the AM SR which was used by over 100 labs 74% of whom were LCCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089826
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447

Showing the most recent 10 out of 1525 publications